drugset
drugset / Trial / NCT04810390

Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children

NCT04810390 ↗

Phase 3 Completed 59 enrolled Faes Farma, S.A. Dynamic Science S.L. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multi-centre, randomised, double blind, placebo-controlled, parallel-group, phase III study to assess the safety, tolerability and efficacy of Bilastine ophthalmic solution 0.6% in children with a documented history of seasonal allergic conjunctivitis (SAC) or perennial allergic conjunctivitis (PAC).

Timeline

Start
2021-03-26
Primary completion
2022-11-30
Completion
2022-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Bilastine Small molecule 0.6 % Other

Indications

conjunctivitis